Kura Oncology
KURA
185 hedge funds and large institutions have $686M invested in Kura Oncology in 2024 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 70 increasing their positions, 36 reducing their positions, and 42 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 36
28% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $939K
14% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 42
3% more funds holding
Funds holding: 180 → 185 (+5)
6.15% less ownership
Funds ownership: 107.48% → 101.34% (-6.1%)
29% less capital inflows, than outflows
Capital inflows: $349M | Capital outflows: $488M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$64M |
| 2 |
Armistice Capital
New York
|
+$45.2M |
| 3 |
Morgan Stanley
New York
|
+$29.7M |
| 4 |
Millennium Management
New York
|
+$21.9M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$106M |
| 2 |
Paradigm Biocapital Advisors
New York
|
-$84.6M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
-$38.4M |
| 4 |
Suvretta Capital Management
New York
|
-$37.1M |
| 5 |
Holocene Advisors
New York
|
-$35.4M |
KURA Hedge Fund Activity: Q4 2024 in Review
185 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2024, worth a combined $686M — down 57% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new KURA positions and 42 closed out — a net gain of 6 holders — while 70 added to existing stakes and 36 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $64M. The largest seller was Deerfield Management, exiting entirely with an estimated $106M sold.
- 185 institutional investors held Kura Oncology (KURA) as of Q4 2024, up from 180 in Q3 2024.
- Funds reported $686M of Kura Oncology stock for Q4 2024, down 57% quarter-over-quarter.
- 48 funds opened new Kura Oncology positions in Q4 2024 and 42 closed out, a net change of +6 holders.
- The largest Kura Oncology buyer in Q4 2024 was RA Capital Management, an estimated $64M added.
- The largest Kura Oncology seller in Q4 2024 was Deerfield Management, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2024.